https://www.ambrosehc.com/news/ambrose-healthcare-strengthens-leadership-team-with-key-senior-appointments 2026-04-09 https://www.ambrosehc.com/news/advancing-rare-disease-through-disciplined-execution 2026-02-26 https://www.ambrosehc.com/news/ambrose-healthcare-welcomes-vir%C3%A1g-stephens-as-chief-of-staff 2025-09-23 https://www.ambrosehc.com/news/ambrose-healthcare-exercises-license-option-for-val401-%E2%80%93-embarks-on-global-development-strategy 2025-09-23 https://www.ambrosehc.com/news/ambrose-healthcare-appoints-dr.-hazel-jones-as-chief-operating-officer-to-accelerate-strategic-growth-and-innovation- 2025-10-09 https://www.ambrosehc.com/news/ambrose-healthcare-wins-best-startup-biotech-company-award-at-obn-awards-2024 2025-08-11 https://www.ambrosehc.com/news/uk-pharma-startup-targets-gulf-for-future-ipo 2025-08-11 https://www.ambrosehc.com/news/pioneering-innovative-approaches-to-clinical-trials 2025-08-11 https://www.ambrosehc.com/news/valirx-ceo-discusses-agreement-to-license-val401-to-ambrose-healthcare 2025-08-11 https://www.ambrosehc.com/news/ambrose-healthcare-publishes-white-paper-on-new-opportunities-in-rare-disease-drug-development. 2025-08-11 https://www.ambrosehc.com/news/option-exercised-for-global-rights-to-renzapride-for-use-in-rare-disease-indication 2025-08-11 https://www.ambrosehc.com/news/leveraging-regulatory-stimuli-in-rare-disease-drug-development 2025-08-11 https://www.ambrosehc.com/news/ambrose-healthcare-supports-rare-disease-day 2025-08-11 https://www.ambrosehc.com/news/ambrose-healthcare-appoints-seasoned-veteran-of-the-healthcare-sector-toby-wilson-waterworth-as-chair-of-the-board-to-lead-the-company-through-next-stage-of-development 2025-08-11 https://www.ambrosehc.com/news/ambrose-healthcare-announces-internationally-recognized-expert%2C-professor-brian-feagan-to-advise-on-rare-disease-and-hospital-drug-product-development 2025-08-11 https://www.ambrosehc.com/news/ambrose-healthcare-announces-collaborations-with-industry-specialists-camrare-and-uk-digital-health 2025-08-11 https://www.ambrosehc.com/news/smartway-pharmaceuticals-and-ambrose-healthcare-agree-early-access-programmes 2025-08-11 https://www.ambrosehc.com/news/ambrose-healthcare-establishes-global-headquarters-in-wales 2025-08-11 https://www.ambrosehc.com/news/rare-disease-clinical-trial-specialist-aparito-joins-ambrose-healthcare%E2%80%99s-collaborative-network-for-the-development-of-new-rare-disease-treatments 2025-08-11 https://www.ambrosehc.com/news/agreement-to-license-val401-to-ambrose-healthcare 2025-08-11 https://www.ambrosehc.com/news/ambrose-healthcare-named-finalist-for-best-start-up-biotech-company-2024 2025-08-11 https://www.ambrosehc.com/news/ambrose-healthcare-appoints-medical-advisory-board-for-next-stage-of-development 2025-08-11 https://www.ambrosehc.com/news/%241-billion-dollar-deals-%E2%80%93-changing-tides-for-rare-disease-treatments%3F 2025-08-11 https://www.ambrosehc.com/news/will-the-green-shoots-in-2024-lead-to-big-change-for-rare-diseases%3F 2025-08-11 https://www.ambrosehc.com/news/six-reasons-why-arab-health-matters 2025-08-11 https://www.ambrosehc.com/news/ambrose-healthcare-wins-national-life-sciences-start-up-of-the-year-award 2025-08-11